ReviewCritical care (London, England)2024
The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II.
Review in Critical care (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Heterogeneity in the response to a high vs low mean arterial pressure target in patients with septic shock a post hoc analysis of a randomized controlled trial.Intensive care medicine · 2025Trial
- [Vasopressors in septic shock: the old and the new].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Review
- Lung-Cardiovascular Interactions and Derangements in ARDS.Comprehensive physiology · 2026Review
- Correlation analysis of serum FGF9, Sestrin2 and HBDH with the severity of sepsis.Journal of medical biochemistry · 2026Article
- Beyond blood pressure: a comprehensive overview of clinical indices in shock and tissue hypoperfusion.Acute and critical care · 2026Article
- The Importance of Plasma Renin Concentrations in Intensive Care Patients with Circulatory Shock.Journal of clinical medicine · 2026Article
- Modulation of the Vasopressin System in Distributive and Cardiogenic Shock: Theoretical Principles and Practical Applications.Journal of clinical medicine · 2026Review
- Perioperative Vasopressor Management in Noncardiac Surgical Patients.Anesthesiology · 2026Article
- Novel aspects of the renin-angiotensin-aldosterone system in septic shock.Current opinion in physiology · 2026Article
- Research trends and hotspots of kidney disease and stem cell therapy from 2009 to 2025: a bibliometric analysis.International urology and nephrology · 2026Article
- Refractory septic shock: our updated pragmatic approach.Journal of anesthesia, analgesia and critical care · 2026Review
- A State-of-the-Art Review Exploring the Cardiovascular Outcomes of Renin-Angiotensin Inhibitors in Acute Kidney Injury.Cardiorenal medicine · 2026Review
- Renin and 1-year mortality in critically ill patients with ARDS: trajectories, discrimination, and survival analysis.Frontiers in medicine · 2026Article
- Reimagining risk stratification: Dipeptidyl peptidase 3 in the new era of cardiovascular biomarkers.World journal of cardiology · 2025Article
- Kidney-organ interactions: recent advances and clinical implications.Current opinion in critical care · 2025Review
- Severe Vasoplegic Syndrome Treated with Angiotensin II and Hemoadsorption Therapy after Cardiac Surgery.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Dysregulation of the renin-angiotensin-aldosterone-system (RAAS) in sepsis is a complex and early phenomenon with a likely significant contribution to organ failure and patient outcomes. A better understanding of the pathophysiology and intricacies of the RAAS in septic shock has led to the use of exogenous angiotensin II as a new therapeutic agent. In this review, we report a multinational and multi-disciplinary expert panel discussion on the role and implications of RAAS modulation in sepsis and the use of exogenous angiotensin II. The panel proposed guidance regarding patient selection and treatment options with exogenous angiotensin II which should trigger further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.